Date published: 2025-9-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

HRG-α Inhibitors

The theoretical class of HRG-α Inhibitors encompasses a broad spectrum of compounds that could indirectly affect the activity or processes involving Histidine-rich glycoprotein or a similarly functioning protein by targeting associated signaling pathways or physiological processes. This class would include anticoagulants, antiplatelets, tyrosine kinase inhibitors, and other agents capable of modulating coagulation, angiogenesis, and immune responses, reflecting the multifaceted roles that proteins like HRG play in these crucial physiological areas.

Through the inhibition of coagulation factors, such as Factor Xa or thrombin, compounds like Rivaroxaban, Apixaban, and Dabigatran illustrate the potential to indirectly influence the coagulation cascade and, by extension, processes involving HRG. Similarly, the targeting of angiogenesis through inhibitors like Sunitinib, Bevacizumab, and Sorafenib showcases the approach to affecting the environment in which HRG operates, particularly in tumor growth and metastasis where angiogenesis plays a critical role. Additionally, the modulation of inflammation and immune responses through agents like Aspirin and natural compounds like Curcumin points to the broader impact that these inhibitors can have on HRG-related pathways.

Collectively, this class highlights the complex interplay between coagulation, angiogenesis, and immune system regulation, underscoring the potential for targeted chemical interventions to modulate the activity of proteins involved in these processes. While direct inhibitors of HRG-α as named do not exist in current scientific discourse, the exploration of indirect modulation provides a valuable framework for understanding how these critical physiological pathways can be influenced by a wide range of chemical agents. This approach not only broadens the scope of potential targets for modulation but also emphasizes the importance of a nuanced understanding of physiological processes in the development of strategies to influence protein function.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Warfarin

81-81-2sc-205888
sc-205888A
1 g
10 g
$72.00
$162.00
7
(1)

Inhibits vitamin K epoxide reductase, potentially affecting coagulation processes where HRG is involved.

Heparin

9005-49-6sc-507344
25 mg
$117.00
1
(0)

Anticoagulant that enhances antithrombin III activity, possibly influencing HRG-related coagulation pathways.

Aspirin

50-78-2sc-202471
sc-202471A
5 g
50 g
$20.00
$41.00
4
(1)

Inhibits COX-1, reducing thromboxane A2 production and potentially affecting platelet function and HRG activity.

Rivaroxaban

366789-02-8sc-208311
2 mg
$155.00
18
(1)

Direct Factor Xa inhibitor, could impact coagulation cascade and processes involving HRG.

Apixaban

503612-47-3sc-364406
sc-364406A
10 mg
50 mg
$235.00
$622.00
2
(1)

Another direct Factor Xa inhibitor, potentially altering coagulation mechanisms involving HRG.

Dabigatran

211914-51-1sc-481166
5 mg
$205.00
1
(0)

Direct thrombin inhibitor, might influence thrombin-mediated processes where HRG plays a role.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Tyrosine kinase inhibitor, could affect angiogenesis and other signaling pathways involving HRG.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

RAF kinase inhibitor, could impact cell signaling and angiogenesis related to HRG function.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

EGFR inhibitor, might affect cell proliferation and pathways where HRG is involved.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Inhibits BCR-ABL tyrosine kinase, potentially affecting cellular signaling related to HRG.